Loading...
The popularity of drugs like Ozempic and Mounjaro, originally designed for diabetes treatment, has surged for weight loss. Questions arise over access to these drugs. A trial reported that semaglutide reduces cardiovascular risk in obese patients. The impact of these drugs on people's relationship with eating and social dynamics is being discussed. Thanksgiving is no longer just about food for many Americans taking appetite suppressing drugs. The drugs, including Wegovy, are also a hot topic in the corporate world. The unintended benefits of these weight-loss drugs are being discovered, and companies like WeightWatchers are adapting to the trend.
"WeightWatchers has acquired a telemedicine company to start prescribing semaglutides via Zoom." https://t.co/4cavKuVoQY
They were intended to treat diabetes. The other benefits of a new generation of weight-loss drugs were discovered by accident https://t.co/QeWA2WKiL2 👇
For Thanksgiving this year our family has decided to take Ozempic and drink whiskey instead of making a fancy turkey dinner
"The consequences of the Ozempic revolution will be economic and social, as well as medical. The new drugs will transform people’s relationship with eating—and with one another," @helenlewis writes: https://t.co/yjZrRj22OE
Obesity and diabetes-focused Carmot plans IPO to push GLP-1 drugs through clinic https://t.co/DYSX7IjGEL
For people taking Ozempic and other weight-loss drugs, Thanksgiving is no longer all about the food https://t.co/LemXiJaSzV
For people taking Ozempic and other weight-loss drugs, Thanksgiving is no longer all about the food https://t.co/PFJgRFOimN by @deenashanker
Weekly injections of the weight loss drug Wegovy cut the number of serious heart problems in a clinical trial. https://t.co/8uhxpyExZT
Weight loss was the talk of this earnings season, making names such as Wegovy, Ozempic and Mounjaro the water-cooler discussion that companies across the globe could not ignore https://t.co/ZeZz1DVQPY
Weight loss was the talk of this earnings season, making names such as Wegovy, Ozempic and Mounjaro the water-cooler discussion that companies across the globe could not ignore. More here: https://t.co/GOxVyrSNmU
Wegovy craze was all the rage on Q3 earnings calls https://t.co/whCpcw4c7u https://t.co/RA1b8yoG3f
Millions of Americans are now taking appetite suppressing hormone injections, and for many this will be their first Thanksgiving on the drug. Food manufacturers and retailers are bracing for an impact that could extend far beyond one or two holidays. https://t.co/jrmrOQRbWZ
For people taking Ozempic and other weight-loss drugs, Thanksgiving is no longer all about the food https://t.co/p7C1YwvVSv via @BW
It’s been the year of Ozempic. Now many Americans are gearing up to face a food-focused holiday while taking a medication that can extinguish one’s appetite. What happens when weight loss drugs collide with Thanksgiving? https://t.co/tOZM1fuZkR
"The consequences of the Ozempic revolution will be economic and social, as well as medical. The new drugs will transform people’s relationship with eating—and with one another," @helenlewis writes: https://t.co/UH7lbzYIiN
A popular obesity medication can also keep the heart healthy — though how exactly it works is a mystery. https://t.co/8uhxpyExZT
"The consequences of the Ozempic revolution will be economic and social, as well as medical. The new drugs will transform people’s relationship with eating—and with one another," @helenlewis writes: https://t.co/4hlJMzWeGs
A new trial has reported that the GLP-1 receptor agonist semaglutide reduces risk of cardiovascular events in patients with obesity – but that’s not the question we ought to be asking. https://t.co/71wqgaOkPT
🔊 💉Drugs like Ozempic and Mounjaro were designed for diabetes treatment. As they soar in popularity for weight loss, questions arise over who should get access. @MaggieFick and @mygershberg talk to @cwalljasper on a Reuters World News special podcast https://t.co/TnZZtpkhwC https://t.co/NwExbQVOOT